Based on the current literature, targeted molecular therapies, including VEGF receptor inhibitors and mTOR inhibitors, have therapeutic advantages over immunotherapy in Xp11.2 tRCC [23]. This evidence concerns the gene MTOR and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.